JP2022514949A5 - - Google Patents
Info
- Publication number
- JP2022514949A5 JP2022514949A5 JP2021536363A JP2021536363A JP2022514949A5 JP 2022514949 A5 JP2022514949 A5 JP 2022514949A5 JP 2021536363 A JP2021536363 A JP 2021536363A JP 2021536363 A JP2021536363 A JP 2021536363A JP 2022514949 A5 JP2022514949 A5 JP 2022514949A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrocarbons
- aliphatic
- hydrogen
- combinations
- halogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199936A JP7751054B2 (ja) | 2018-12-21 | 2024-11-15 | リファマイシンアナログおよびその抗体薬物コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783506P | 2018-12-21 | 2018-12-21 | |
| US62/783,506 | 2018-12-21 | ||
| US201962844860P | 2019-05-08 | 2019-05-08 | |
| US62/844,860 | 2019-05-08 | ||
| PCT/US2019/067914 WO2020132483A1 (en) | 2018-12-21 | 2019-12-20 | Rifamycin analogs and antibody-drug conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199936A Division JP7751054B2 (ja) | 2018-12-21 | 2024-11-15 | リファマイシンアナログおよびその抗体薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514949A JP2022514949A (ja) | 2022-02-16 |
| JP2022514949A5 true JP2022514949A5 (https=) | 2022-12-27 |
| JP7591503B2 JP7591503B2 (ja) | 2024-11-28 |
Family
ID=69326667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536363A Active JP7591503B2 (ja) | 2018-12-21 | 2019-12-20 | リファマイシンアナログおよびその抗体薬物コンジュゲート |
| JP2024199936A Active JP7751054B2 (ja) | 2018-12-21 | 2024-11-15 | リファマイシンアナログおよびその抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199936A Active JP7751054B2 (ja) | 2018-12-21 | 2024-11-15 | リファマイシンアナログおよびその抗体薬物コンジュゲート |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11666658B2 (https=) |
| EP (1) | EP3897841A1 (https=) |
| JP (2) | JP7591503B2 (https=) |
| KR (1) | KR102876950B1 (https=) |
| CN (2) | CN113226470B (https=) |
| AU (2) | AU2019403404B2 (https=) |
| BR (1) | BR112021012233A2 (https=) |
| CA (1) | CA3123607A1 (https=) |
| CL (3) | CL2021001644A1 (https=) |
| CO (1) | CO2021009396A2 (https=) |
| IL (2) | IL318210A (https=) |
| MA (2) | MA66057B2 (https=) |
| MX (1) | MX2021007524A (https=) |
| MY (1) | MY207057A (https=) |
| NZ (1) | NZ777641A (https=) |
| PH (1) | PH12021551476A1 (https=) |
| SG (1) | SG11202106658XA (https=) |
| WO (1) | WO2020132483A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3046537T3 (en) | 2016-11-08 | 2025-12-02 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| SG11202006510XA (en) | 2018-01-08 | 2020-08-28 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| US20220143194A1 (en) | 2020-11-10 | 2022-05-12 | Regeneron Pharmaceuticals, Inc. | Selenium antibody conjugates |
| ES3017798T3 (en) * | 2021-03-26 | 2025-05-13 | Regeneron Pharma | Rifamycin analogs in combination with vancomycin and uses thereof |
| CN117147824A (zh) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | 一种抗体缀合物及其应用 |
| CN115057871B (zh) * | 2022-08-17 | 2022-11-15 | 北京丹大生物技术有限公司 | 利福平半抗原衍生物、利福平完全抗原、利福平抗体及应用 |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| CN119950541B (zh) * | 2025-01-10 | 2025-11-21 | 中国人民解放军总医院第一医学中心 | Msr1基因作为靶点在筛选脓毒症防治药物中的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59231092A (ja) * | 1983-06-11 | 1984-12-25 | Kanebo Ltd | フエノチアジン型リフアマイシンおよびその医薬用途 |
| JPS6345282A (ja) * | 1986-04-14 | 1988-02-26 | Kanegafuchi Chem Ind Co Ltd | アシル基及び置換アルキル基を有するリフアマイシン誘導体 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JPH01207293A (ja) * | 1987-03-24 | 1989-08-21 | Kanegafuchi Chem Ind Co Ltd | 置換ベンゾキサジノリフアマイシン誘導体 |
| JPH01175938A (ja) * | 1987-12-29 | 1989-07-12 | Kanegafuchi Chem Ind Co Ltd | ウイルス感染症治療剤 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| US20080051805A1 (en) | 2006-08-28 | 2008-02-28 | Leonard Pinchuk | Hair Follicle Coring Tool and System Based Thereon |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| DK2121920T3 (da) | 2007-03-01 | 2011-11-21 | Symphogen As | Fremgangsmåde til kloning af sammenhørende antistoffer |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| RU2014124984A (ru) | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| PL3366705T3 (pl) | 2012-09-12 | 2023-09-18 | Genzyme Corporation | FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI692483B (zh) | 2013-05-31 | 2020-05-01 | 美商建南德克公司 | 抗壁磷壁酸抗體（ａｎｔｉ-ｗａｌｌ ｔｅｉｃｈｏｉｃ ａｃｉｄ ａｎｔｉｂｏｄｉｅｓ）及結合物 |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| HK1243931A1 (zh) | 2014-12-03 | 2018-07-27 | F. Hoffmann-La Roche Ag | 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途 |
| BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| KR102204805B1 (ko) * | 2016-03-04 | 2021-01-20 | 제넨테크, 인크. | 항체-리파마이신 접합체의 제조 방법 |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| JP7365830B2 (ja) * | 2019-09-17 | 2023-10-20 | テルモ株式会社 | 医療器具および医療器具の製造方法 |
-
2019
- 2019-12-20 PH PH1/2021/551476A patent/PH12021551476A1/en unknown
- 2019-12-20 CN CN201980085251.5A patent/CN113226470B/zh active Active
- 2019-12-20 MA MA66057A patent/MA66057B2/fr unknown
- 2019-12-20 AU AU2019403404A patent/AU2019403404B2/en active Active
- 2019-12-20 KR KR1020217022821A patent/KR102876950B1/ko active Active
- 2019-12-20 IL IL318210A patent/IL318210A/en unknown
- 2019-12-20 NZ NZ777641A patent/NZ777641A/en unknown
- 2019-12-20 BR BR112021012233-8A patent/BR112021012233A2/pt unknown
- 2019-12-20 SG SG11202106658XA patent/SG11202106658XA/en unknown
- 2019-12-20 IL IL284007A patent/IL284007B2/en unknown
- 2019-12-20 EP EP19842960.7A patent/EP3897841A1/en active Pending
- 2019-12-20 CA CA3123607A patent/CA3123607A1/en active Pending
- 2019-12-20 MA MA054545A patent/MA54545A/fr unknown
- 2019-12-20 MX MX2021007524A patent/MX2021007524A/es unknown
- 2019-12-20 WO PCT/US2019/067914 patent/WO2020132483A1/en not_active Ceased
- 2019-12-20 CN CN202510479153.7A patent/CN120309630A/zh active Pending
- 2019-12-20 JP JP2021536363A patent/JP7591503B2/ja active Active
- 2019-12-20 US US16/722,958 patent/US11666658B2/en active Active
- 2019-12-20 MY MYPI2021003466A patent/MY207057A/en unknown
-
2021
- 2021-06-18 CL CL2021001644A patent/CL2021001644A1/es unknown
- 2021-07-19 CO CONC2021/0009396A patent/CO2021009396A2/es unknown
-
2022
- 2022-12-28 US US18/090,138 patent/US20230285581A1/en active Pending
-
2023
- 2023-06-23 CL CL2023001894A patent/CL2023001894A1/es unknown
-
2024
- 2024-11-15 JP JP2024199936A patent/JP7751054B2/ja active Active
-
2025
- 2025-03-21 CL CL2025000841A patent/CL2025000841A1/es unknown
- 2025-08-26 AU AU2025223742A patent/AU2025223742A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514949A5 (https=) | ||
| IL318210A (en) | Rifampicin analogs and their antibody-drug conjugates | |
| JP2022537158A5 (https=) | ||
| RU2016139340A (ru) | Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой | |
| TWI589592B (zh) | 胞毒性肽類以及其抗體藥物共軛體 | |
| US11819553B2 (en) | Glypican 3 antibodies and conjugates thereof | |
| TWI790996B (zh) | 用於製備聚乙二醇化的藥物－連接劑及其中間體之方法 | |
| AU2016232839B2 (en) | CD48 antibodies and conjugates thereof | |
| WO2022207699A1 (en) | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties | |
| JP2022512778A5 (https=) | ||
| TWI660741B (zh) | 抗體藥物複合物及其製造方法 | |
| JP2017537893A5 (https=) | ||
| US20110097322A1 (en) | Partially loaded antibodies and methods of their conjugation | |
| JP2021513990A5 (https=) | ||
| CN118973617A (zh) | 缀合物、组合物及使用方法 | |
| TW201400131A (zh) | 自行穩定之接合劑共軛物 | |
| WO2021067820A1 (en) | Formulation of antibody-drug conjugate | |
| RU2018102358A (ru) | Нацеленные конъюгаты ksp ингибиторов | |
| TW202410920A (zh) | 包括聚合物賦形劑之抗體生物醫藥調配物 | |
| TW201822820A (zh) | 連接子藥物及包含其之抗體藥物複合物（ａｄｃ） | |
| WO2024235136A9 (zh) | 杂环类化合物及其制备方法和用途 | |
| WO2024235134A9 (zh) | 具有靶向作用的偶联物及其制备方法和用途 | |
| KR910000179A (ko) | Aids용 결합체 면역원 | |
| CN114106088A (zh) | 基于溴甲基吡嗪的药物偶联物及adc | |
| CN121574085A (zh) | 缀合物及其用途 |